Haemonetics
285 hedge funds and large institutions have $4.44B invested in Haemonetics in 2020 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 103 increasing their positions, 97 reducing their positions, and 41 closing their positions.
44% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 41
6% more funds holding
Funds holding: 269 → 285 (+16)
6% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 97
2.44% less ownership
Funds ownership: 100.81% → 98.36% (-2.4%)
12% less capital invested
Capital invested by funds: $5.05B → $4.44B (-$610M)
60% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $29.1M
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$111M |
| 2 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$50.5M |
| 3 |
Neuberger Berman Group
New York
|
+$44.7M |
| 4 |
Morgan Stanley
New York
|
+$39.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$143M |
| 2 |
BlackRock
New York
|
-$88.6M |
| 3 |
EC
Eminence Capital
New York
|
-$84.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$72.1M |
| 5 |
Goldman Sachs
New York
|
-$66.9M |
HAE Hedge Fund Activity: Q2 2020 in Review
285 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2020, worth a combined $4.44B — down 12% from $5.05B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new HAE positions and 41 closed out — a net gain of 18 holders — while 103 added to existing stakes and 97 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $111M. The largest seller was HealthCor Management, exiting entirely with an estimated $143M sold.
- 285 institutional investors held Haemonetics (HAE) as of Q2 2020, up from 269 in Q1 2020.
- Funds reported $4.44B of Haemonetics stock for Q2 2020, down 12% quarter-over-quarter.
- 59 funds opened new Haemonetics positions in Q2 2020 and 41 closed out, a net change of +18 holders.
- The largest Haemonetics buyer in Q2 2020 was Capital Research Global Investors, an estimated $111M added.
- The largest Haemonetics seller in Q2 2020 was HealthCor Management, an estimated $143M sold.
Based on aggregated 13F filings for Q2 2020.